Seroepidemiology of diphtheria and tetanus among children and young adults in Tajikistan: Nationwide population-based survey, 2010KHETSURIANI, Nino; ZAKIKHANY, Katherina; JABIROV, Shamsiddin et al.Vaccine. 2013, Vol 31, Num 42, pp 4917-4922, issn 0264-410X, 6 p.Article

Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccinesGIULIANO, M; MASTRANTONIO, P; GIAMMANCO, A et al.Developments in biological standardization. 1997, Num 89, pp 275-278, issn 0301-5149Conference Paper

Methods for estimating serological correlates of protectionSIBER, G. R.Developments in biological standardization. 1997, Num 89, pp 283-296, issn 0301-5149Conference Paper

Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacyHEWLETT, E. L.Developments in biological standardization. 1997, Num 89, pp 143-151, issn 0301-5149Conference Paper

A consideration of control requirements for acellular pertussis vaccinesCORBEL, M. J; XING, D. K. L.Developments in biological standardization. 1997, Num 89, pp 343-347, issn 0301-5149Conference Paper

Absolute efficacy of acellular pertussis vaccines in household settingsSTORSAETER, J; GUSTAFSSON, L.Developments in biological standardization. 1997, Num 89, pp 153-158, issn 0301-5149Conference Paper

Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trialTARANGER, J; TROLLFORS, B; KNUTSSON, N et al.Developments in biological standardization. 1997, Num 89, pp 109-112, issn 0301-5149Conference Paper

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?GRANOFF, D. M; RAPPUOLI, R.Developments in biological standardization. 1997, Num 89, pp 379-389, issn 0301-5149Conference Paper

Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine : Comparison of the T cell cytokine profiles in infants and miceRYAN, M; GOTHEFORS, L; STORSAETER, J et al.Developments in biological standardization. 1997, Num 89, pp 297-305, issn 0301-5149Conference Paper

Factors influencing the analysis of secondary prevention of pertussisWIRSING VON KÖNIG, C. H; SCHMITT, H. J; BOGAERTS, H et al.Developments in biological standardization. 1997, Num 89, pp 175-179, issn 0301-5149Conference Paper

Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial IIHEIJBEL, H; RASMUSSEN, F; OLIN, P et al.Developments in biological standardization. 1997, Num 89, pp 99-100, issn 0301-5149Conference Paper

The effectiveness of whole-cell pertussis vaccinesPLOTKIN, S. A.Developments in biological standardization. 1997, Num 89, pp 171-174, issn 0301-5149Conference Paper

A comparison of enzyme immuno-assays used to measure serum antibodies to components of Bordetella pertussisLYNN, F; REED, G. F; MEADE, B. D et al.Developments in biological standardization. 1997, Num 89, pp 197-204, issn 0301-5149Conference Paper

Common side effects in the Italian and Stockholm I trialsTOZZI, A. E; OLIN, P.Developments in biological standardization. 1997, Num 89, pp 105-108, issn 0301-5149Conference Paper

Comparison of serological results in the NIAID multicenter acellular pertussis trial with recent efficacy trialsEDWARDS, K. M; DECKER, M. D.Developments in biological standardization. 1997, Num 89, pp 265-273, issn 0301-5149Conference Paper

European union research strategies on vaccinesHANSEN, B.Developments in biological standardization. 1997, Num 89, pp 29-36, issn 0301-5149Conference Paper

Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussisSCHNEERSON, R; ROBBINS, J. B; TARANGER, J et al.Developments in biological standardization. 1997, Num 89, pp 321-326, issn 0301-5149Conference Paper

Implications of different study designs for the evaluation of acellular pertussis vaccinesFINE, P. E. M.Developments in biological standardization. 1997, Num 89, pp 123-133, issn 0301-5149Conference Paper

Issues regarding future research on pertussis vaccinesBURNS, D.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.377Conference Paper

Regulatory issues concerning pertussis vaccinesTIRU, M.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.341Conference Paper

Some thoughts for future pertussis research in EuropePLETSCHETTE, M.Developments in biological standardization. 1997, Num 89, issn 0301-5149, p.391Conference Paper

International Symposium on Pertussis Vaccine TrialsBROWN, Fred; GRECO, Donato; MASTRANTONIO, Paola et al.Developments in biological standardization. 1997, Num 89, issn 0301-5149, 423 p.Conference Proceedings

Absolute and relative efficacy of whole-cell vaccinesJAFARI, H. S.Developments in biological standardization. 1997, Num 89, pp 167-170, issn 0301-5149Conference Paper

Case definitionsSALMASO, S; MOIRAGHI, A; BARALE, A et al.Developments in biological standardization. 1997, Num 89, pp 135-142, issn 0301-5149Conference Paper

Estimation of pertussis vaccine efficacy in the presence of covariates in three randomized trialsBLACKWELDER, W. C; VANRADEN, M. J; DELORIA, M. A et al.Developments in biological standardization. 1997, Num 89, pp 161-166, issn 0301-5149Conference Paper